Metafort-G 851 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. Metafort-G 851 Tablet PR is designed for prolonged release, ensuring sustained therapeutic plasma concentrations, which may improve patient compliance and reduce gastrointestinal side effects commonly associated with immediate-release formulations. It is recommended to be administered with meals to minimize potential adverse effects such as nausea or hypoglycemia. Regular monitoring of blood glucose, renal function, and hepatic parameters is advised during therapy. Caution is warranted in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia. Metafort-G 851 Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision to optimize glycemic control and reduce the risk of diabetes-related complications.